NICE final draft guidance recommends once-weekly insulin efsitora alfa for type 2 diabetes

What was announced

NICE has recommended insulin efsitora alfa, sold as Onswik and made by Eli Lilly, for adults with type 2 diabetes. This was final draft guidance. It is injected once a week, and NICE says this could cut injections from 365 a year to 52. NICE says it gives blood glucose control similar to people's current treatment, and can be used alone or alongside other treatments.

What it means

NICE expects the biggest benefit for people who need a carer or family member to help with injections, and for those with extra care needs. The draft says the medicine must be licensed by the MHRA before it can be made available on the NHS. It also says healthcare professionals and patients should discuss the options and choose the least expensive treatment that meets the person's needs. NICE's guidance page for the appraisal (TA1200) lists final guidance as published on 16 October 2026.